Showing results (261-270 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2013
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcomeKatia Todoerti, Luca Agnelli, Sonia Fabris, et al.
Non-Coding RNA|September 23, 2024
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective StudyEnnio Nano, Francesco Reggiani, Adriana Agnese Amaro, et al.
Haematologica|October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complicationsEvangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Leukemia & Lymphoma|April 11, 2015
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Laura Mosca, et al.
European Journal of Haematology|March 11, 2015
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Stefano Molica, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
American Journal of Hematology|October 10, 2012
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profilesLaura Mosca, Pellegrino Musto, Katia Todoerti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemiaMarta Lionetti, Pellegrino Musto, Maria Teresa Di Martino, et al.
Pageof 31